文献速递神经免疫

硫辛酸治疗进展型多发性硬化:2期随机临床试验

Lipoic Acid for Treatment of Progressive Multiple Sclerosis: A Phase 2 Randomized Clinical Trial.
PubMed 文献 · Neurology · 2025-12-15

这项2期随机双盲安慰剂对照试验纳入118例进展型多发性硬化患者,评估每日口服1200mg硫辛酸24个月的效果。结果显示硫辛酸未减缓步行速度下降,也未改善其他临床结局,但全脑和深部灰质体积保持稳定;硫辛酸组蛋白尿更多、自杀意念事件更少。

要点

  • 硫辛酸未减缓进展型多发性硬化患者24个月步行速度下降。
  • 硫辛酸组全脑和深部灰质体积稳定,安慰剂组有下降趋势。
  • 硫辛酸组蛋白尿增加、自杀意念事件减少,需关注新不良事件。

核心结论

  • 口服硫辛酸未改善进展型多发性硬化患者24个月时的计时步行速度,临床效果与安慰剂无差异。
  • 硫辛酸与全脑和深部灰质体积稳定相关,但伴随新描述的不良事件。

研究设计与样本

  • 2期、24个月、随机、双盲、安慰剂对照临床试验(2018-2023),从美国10个中心(含5个退伍军人医疗中心)和1个加拿大中心方便抽样。
  • 纳入年龄≥18岁、原发或继发进展型多发性硬化、EDSS评分3.0-6.5、过去2年非复发相关残疾恶化的患者,允许合并疾病修饰治疗。
  • 按中心区组随机(1:1)分配至每日口服硫辛酸1200mg或安慰剂,样本量118例,检验Timed 25-Foot Walk速度差异,允许25%脱落。

主要发现

  • 硫辛酸组54例、安慰剂组61例,女性占54.8%,平均年龄59.1岁(SD 8.5),平均病程16.3年(SD 9.7),EDSS中位数6.0(IQR 4.0-6.0),55.7%使用疾病修饰治疗。
  • 硫辛酸组全脑体积似乎稳定,安慰剂组呈下降趋势,即使考虑硫辛酸组总T2加权病灶体积增加更明显后仍如此;深部灰质体积在硫辛酸组稳定、安慰剂组下降。
  • 硫辛酸组蛋白尿更多、自杀意念事件少于安慰剂组;硫辛酸组研究脱落率37%,安慰剂组17%。

临床怎么用

  • 不推荐使用口服硫辛酸1200mg/日来延缓进展型多发性硬化的步行速度下降。
  • 硫辛酸治疗期间需监测蛋白尿,并关注自杀意念等不良事件。
  • 硫辛酸对脑体积指标的影响需进一步研究,暂不能作为神经保护依据。

局限性

  • 采用方便抽样,可能影响代表性。
  • 硫辛酸组脱落率(37%)高于安慰剂组(17%),可能影响结果解释。
  • 研究仅提供2期证据,需更大规模试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: A pilot trial of the antioxidant lipoic acid (LA) in secondary progressive multiple sclerosis (MS) demonstrated a reduction in the whole-brain atrophy, suggesting neuroprotection. This study determined whether LA preserved walking speed, reduced brain atrophy, and was safe in progressive MS (PMS). METHODS: This phase 2, 24-month, randomized, double-blind, placebo-controlled clinical trial (2018-2023) recruited a convenience sample from 10 US sites, including 5 Veterans Affairs medical centers and 1 Canadian site. Inclusion criteria were as follows: age ≥18 years, primary or secondary PMS, Expanded Disability Status Scale (EDSS) score 3.0-6.5, and relapse-independent disability worsening in the previous 2 years. Exclusion criteria were as follows: confounders of mobility outcomes, LA use in the previous 2 years, and MRI contraindications. Concurrent disease-modifying therapy (DMT) was permitted. Participants were block-randomized by site (1:1) to receive 1,200 mg daily oral LA or placebo. The sample size (n = 118) was powered to detect Timed 25-Foot Walk (primary outcome) speed differences, allowing 25% attrition. Secondary outcomes were brain atrophy, other clinical and patient-reported disabilities, and adverse events. Study visits occurred every 6 months. Laboratory monitoring was increased to every 3 months because of treatment-related proteinuria. Intention-to-treat analysis used linear mixed-effects models. RESULTS: Participants in the LA (54) and placebo (61) groups were 54.8% female (age 59.1 (SD 8.5) years), with a disease duration of 16.3 (SD 9.7) years and a median EDSS score of 6.0 (interquartile range 4.0-6.0), and 55.7% were on DMT. Groups were matched at baseline. LA participants discontinued from the study more often (37%) than placebo (17%). LA did not slow declines in walking speed (-0.39 ft/sec vs -0.30 ft/sec; -0.08 [-0.33 to 0.17]), nor showed differences in mobility, other clinical, or patient-reported outcomes from placebo. Whole-brain volume seemed stable in LA participants, whereas it trended toward a decrease in placebo, even after accounting for an increased total T2-weighted lesion volume that was greater in the LA group. Deep gray matter volume remained stable in LA participants and decreased in placebo participants. The LA group experienced more proteinuria and fewer suicidal ideation events than the placebo group. DISCUSSION: LA did not slow decline in walking speed or have other clinical effects different from placebo and was associated with newly described adverse events. Investigating LA mechanisms may help interpretation of volumetric imaging biomarkers in PMS. TRIAL REGISTRATION INFORMATION: NCT03161028. clinicaltrials.gov/study//NCT03161028, first submission May 18, 2017; first patient enrolled August 17, 2018. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that in people with primary or secondary PMS, oral LA did not improve timed walking speed at 24 months compared with placebo.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Spain RI, Paz Soldán MM, Freedman MS, et al. Lipoic Acid for Treatment of Progressive Multiple Sclerosis: A Phase 2 Randomized Clinical Trial. Neurology. 2025. PMID: 41397213. doi:10.1212/WNL.0000000000214454

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。